We have chosen clone 22C3, which is the most used for pembrolizumab eligibility [21]; we found that PD-L1 did not show staining of tumor cells in the invasive carcinoma, IDC, or in cells displaying PS. The gene discussed is CD274; the disease is invasive carcinoma.